LMB vs GYRE Comparison

Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.